Caribou Biosciences, Inc. (CRBU)
Chart Events
Performance Outlook
| Previous Close | 8.64 |
| Open | 8.76 |
| Bid | 8.20 x 1000 |
| Ask | 8.23 x 800 |
| Day's Range | 8.05 - 9.06 |
| 52 Week Range | 6.41 - 32.65 |
| Volume | |
| Avg. Volume | 677,722 |
| Market Cap | 491.107M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.64 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.43 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CRBU
Related Research
- Caribou Biosciences, Inc.Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.RatingFair ValueEconomic Moat10 days agoMorningstar
- GlobeNewswire
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
-- Data presented at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) --BERKELEY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the presentation of studies in primary human T cells highlighting the mechanism underlying the superior specificity of the company’s CRISPR hybrid RNA-DNA (chRDNA) guides for genome editing. “Our chRDNA guides pr
- Benzinga
Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
Caribou Biosciences Inc (NASDAQ: CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). These initial data will be shared at the European Hematology Association (EHA) 2022 Hybrid Congress. The EHA abstract includes safety, tolerability, and initial antitumor activity of CB-010 administered at dose level 1 (40x106 CAR-T cells) to 6 patients with r/r B-NHL who had relapsed after previous treatment. As of the February
- GlobeNewswire
Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
Patient response rates following treatment with CB-010, single dose at dose level 1, in the ANTLER Phase 1 trial Footnote: data cutoff date of February 23, 2022, data collection ongoing, efficacy based on Lugano criteria -- 100% ORR (5 of 5 patients) and 80% CR (4 of 5 patients) achieved following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- CB-010 is the 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5 of 5 patients) -- -- Based on promising initial safet
